FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 09/2024”. The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of September 2024 we identified the following current VC trends in Europe:
- Total Healthcare & Life Sciences funding reached EUR 6,507m
- Biotech/Pharma received 60% of the total investment volume (EUR 3,939m) with oncology being the leading indication (46%)
- In September, Pantera (Belgium) secured the highest transaction volume with EUR 134m, followed by F2G (United Kingdom) with EUR 90m and ViceBio (United Kingdom) with EUR 90m
- General Atlantic (United States) is the most active investor (by deal volume in 2024), followed by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To access the full report, please click here.